


PDK4-IN-1

Cat. No.:	HY-135954
CAS No.:	2310262-10-1
Molecular Formula:	C ₂₂ H ₁₉ N ₃ O ₂
Molecular Weight:	357.41
Target:	PDHK; Apoptosis
Pathway:	Metabolic Enzyme/Protease; Apoptosis
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (279.79 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.7979 mL	13.9895 mL	27.9791 mL
	5 mM	0.5596 mL	2.7979 mL	5.5958 mL
	10 mM	0.2798 mL	1.3990 mL	2.7979 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PDK4-IN-1 is an anthraquinone derivative and a potent and orally active pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC₅₀ value of 84 nM. PDK4-IN-1 potently represses cellular transformation and cellular proliferation and induces apoptosis. PDK4-IN-1 has antidiabetic, anticancer and anti-allergic activity^[1].

IC₅₀ & Target

IC₅₀: 84 nM (Pyruvate dehydrogenase kinase 4 (PDK4))^[1]

In Vitro

PDK4-IN-1 (Compound 8c; 50 μM; 0-72 hours; HCT116 and RKO cells) treatment significantly impedes the proliferation of human colon cancer cell lines, HCT116 and RKO. The colony formation efficiency in HCT116 and RKO cells is significantly reduced after treatment of PDK4-IN-1^[1].

PDK4-IN-1 (Compound 8c; 10-50 μM; 24 hours; HCT116 and RKO cells) treatment dose-dependently increased apoptosis^[1].

PDK4-IN-1 (Compound 8c; 10 μM; 24 hours; HEK293T cells) treatment inhibits phosphorylation of Ser²³², Ser²⁹³, and Ser³⁰⁰ of PDHE1α^[1].

10 μM of PDK4-IN-1 (Compound 8c) significantly increases p-Akt in AML12 cells^[1].

PDK4-IN-1 (compound 8c)-induced phosphorylation of p53 on serine 15 is a dose-dependent response in both HCT116 and RKO cells. PDK4-IN-1 decreases the expression of BCL-xL and increases the expression of BAX. Cleavage of PARP1 and caspase 3 are increased by PDK4-IN-1^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HCT116 and RKO cells
Concentration:	50 μ M
Incubation Time:	0 hour, 24 hours, 48 hours, 72hours
Result:	Significantly impeded the proliferation of human colon cancer cell lines, HCT116 and RKO.

Apoptosis Analysis^[1]

Cell Line:	HCT116 and RKO cells
Concentration:	10 μ M, 25 μ M, 50 μ M
Incubation Time:	24 hours
Result:	Dose-dependently increased apoptosis.

Western Blot Analysis^[1]

Cell Line:	HEK293T human embryonic kidney cells
Concentration:	10 μ M
Incubation Time:	24 hours
Result:	Inhibited phosphorylation of Ser ²³² , Ser ²⁹³ , and Ser ³⁰⁰ of PDHE1 α .

In Vivo

PDK4-IN-1 (Compound 8c; 100 mg/kg; oral administration; daily; for 1 week; C57BL/6J mice) treatment significantly improves glucose tolerance^[1].

Pre-incubation with PDK4-IN-1 (compound 8c) dose-dependently inhibits the release of β -hexosaminidase from IgE/antigen-activated BMMCs, showing that the absorbance values are 0.26, 0.20, and 0.126 in IgE/Ag, 10 μ M, and 20 μ M PDK4-IN-1-treated BMMCs^[1].

The pharmacokinetic (PK) profiles of PDK4-IN-1 (compound 8c) are evaluated in rat. PDK4-IN-1 shows good bioavailability (64%), long half-life (>7 h), and moderate clearance (CL of 0.69) in rats^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice (8-week old) fed with high-fat diet ^[1]
Dosage:	100 mg/kg
Administration:	Oral administration; daily; for 1 week
Result:	Significantly improved glucose tolerance.

CUSTOMER VALIDATION

- Aging Cell. 2023 Feb 16;e13800.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lee D, et al. Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases. J Med Chem. 2019 Jan 24;62(2):575-588.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA